NCT04491084: A reported trial by Albert Einstein College of Medicine
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04491084 |
|---|---|
| Title | FLT3 Ligand (CDX-301), CD40 Agonist Antibody (CDX-1140), and Stereotactic Radiotherapy Versus Standard Therapy for Advanced Non-small Cell Lung Cancer: A Phase I/II Randomized Trial |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 1, 2021 |
| Completion date | Aug. 18, 2022 |
| Required reporting date | Aug. 18, 2023, midnight |
| Actual reporting date | June 23, 2023 |
| Date last checked at ClinicalTrials.gov | Nov. 17, 2025 |
| Days late | None |